FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab
The U.S. Food and Drug Administration (FDA) has rejected the approval of the cancer drug Ivonescimab submitted by Summit Therapeutics, which was originally developed by China's Kangfang Biotech. Summit Therapeutics is headquartered in Miami, and on Monday, Kangfang Biotech's stock, listed in Hong Kong, fell by 24%. In 2022, Kangfang Biotech licensed the drug to Summit, with a total transaction value of up to $5 billion. In September of this year, AstraZeneca invested $2 billion in Summit and acquired an 11% stake. The FDA stated that the drug has not established sufficient evidence of efficacy and has not shown a significant improvement in patient survival rates. Summit's co-CEO Robert Duggan expressed disappointment regarding this decision. The approval of Ivonescimab by the FDA was one of the first applications for treatment regimens targeting multiple cancers. Analysts pointed out that this rejection was not unexpected and should not affect the applications for the company's other drugs. Among the clinical trial data submitted to the FDA, 62% of the participants were Asian, while 38% were Western, and investment bank TD Cowen raised concerns that the patient composition might influence the FDA's decision. Kangfang Biotech is regarded as a leading company in China's biotechnology industry and secured a significant presentation slot at the American Society of Clinical Oncology (ASCO) annual meeting in June of this year.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Sellas Life Sciences Cancer Vaccine Extends Patient Survival in Blood Cancer Clinical Trial

Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

Three wallets hoard $52.7M on XRP’s sidechain, and nobody is trading it

End of AI Boom? Bank of America Monthly Survey: Fund Managers Cut Tech Stock Positions by Largest Margin in 20 Years

Nvidia's Controversy: AMD's CEO Lisa Su Praises Jensen Huang, Data Center Business Expected to Account for 80% Next Year

Alphabet vs. Amazon: Which Is the Better AI Cloud Stock to Own for the Next 5 Years?

Worried About Nvidia? 3 Artificial Intelligence (AI) Stocks That May Be Safer Buys Right Now

Further Arrests in the Zondacrypto Scandal. Prosecutor Talks About Three Individuals

Bitcoin developer verifies 164 million unspent coins in just 72 seconds

4 Dates That Could Move the Stock Market in Epic Fashion This Week. Here's What Investors Need to Know.

CFTC puts tokenization and margin on Dec. 15 trading agenda

South Korea’s Toss Plans Ethereum Wallet for ETH, USDT and USDC Inside Its Finance App

Druckenmiller Turns Bearish on Copper Prices, Zeroes Out Stock Positions, Says Current Market Visibility is Lowest in Memory

From ETH to BTC: What is THORChain and what can investigators track

Tether’s Paolo Ardoino backs RGB for Bitcoin tokenization

Prediction: These Will Be Nvidia’s and AMD’s Stock Prices by the End of 2027 (Hint: Only 1 Is a Buy).

Trezor Warns 27,000 Shipping Orders Were Exposed in Partner Breach, Not Wallet Keys

Fed’s Waller says blockchain is forcing banks to compete

Solana Drops “Mainnet Beta” Label as Foundation Introduces Protocol Version 1.0

Where Will Nvidia Stock Be in 3 Years?







